Bmi‐1 expression predicts prognosis for patients with gastric carcinoma

Liu, Jian Hua; Song, Li; Zhang, Xing; Guo, Bingbing; Feng, Yan; Li, Xue Xian; Liao, Wen Ting; Zeng, Mu Sheng; Huang, Kai

doi:10.1002/jso.20934

Cited by 73 publications

(66 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 In previous NSCLC studies, Vonlanthen et al 18 reported no association of Bmi1 expression with tumor characteristics (proliferation rate, differentiation, and size) or prognosis, whereas Vrzalikova et al 20 reported that Bmi1 expression was correlated with advanced stage and poor disease-free survival, but not with overall survival. For other types of cancer, some studies demonstrated that overexpression of Bmi1 was correlated with a poor prognosis [42][43][44] ; however, others reported that loss of Bmi1 expression was correlated with an aggressive phenotype, indicating a protective role of the Bmi1 protein. [45][46][47] Abundant expression of Bmi1 in normal bronchial epithelial cells in the current study and in a previous report 19 and low Bmi1 expression in the majority of tumor cells suggest that Bmi1 may have a protective role in NSCLC.…”

Section: Bmi1 and Ezh2 Expression In Nsclc/kikuchi Et Almentioning

confidence: 99%

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

Kikuchi

Kinoshita

Shimizu

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The polycomb group genes Bmi1 polycomb ring finger oncogene (Bmi1) and enhancer of zeste homolog 2 (EZH2) function as transcriptional repressors involved in gene silencing and in the malignant transformation and biologic aggressiveness of several human carcinomas. In the current study, the authors evaluated Bmi1 and EZH2 protein expression in specimens of human nonsmall cell lung cancer (NSCLC). METHODS: The authors conducted an immunohistochemical assessment of 157 surgically resected NSCLCs to evaluate the correlation between Bmi1 and EZH2 expression and various features, including clinical, clinicopathologic, and biologic characteristics. RESULTS: Normal bronchial epithelia revealed abundant expression of Bmi1 and sporadic expression of EZH2. Patients who had high EZH2 expression in tumor cells had a poorer prognosis than patients who had low EZH2 expression in tumor cells all pathologic stages of NSCLC (P ¼.001) and in pathologic stage I NSCLC (P ¼.006). Multivariate analysis revealed that high EZH2 expression was a independent, unfavorable prognostic factor in patients with pathologic stage I disease (P ¼.048). High EZH2 expression was correlated significantly with nonadenocarcinoma histology (P ¼.001), moderate and poor differentiation (P ¼.001), advanced pathologic tumor classification (P ¼.02), and high Ki-67 and cyclin E labeling indices (P < .001). Bmi1 expression, in contrast, was not a significant prognostic factor and was not correlated with any clinicopathologic factors other than early pathologic tumor classification. CONCLU-SIONS: Bmi1 and EZH2 had characteristic and distinctive expression in NSCLCs. High EZH2 expression was correlated with tumor aggressiveness and may provide a novel prognostic marker for NSCLCs. Cancer 2010;116:3015-24.

show abstract

Section: Bmi1 and Ezh2 Expression In Nsclc/kikuchi Et Almentioning

confidence: 99%

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

Kikuchi

Kinoshita

Shimizu

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…Aberrant Bmi-1 expression has been reported in a variety of human cancers [8][9][10][11][12][13]. In our previous study, Bmi-1 expression was correlated with tumor size, clinical stage, and prognosis for patients with gastric carcinoma [14]. Patients with Bmi-1 expression had a shorter overall survival time than those without Bmi-1 expression.…”

Section: Introductionmentioning

confidence: 77%

“…The tissue microarray blocks were cut into 5-lm sections for immunohistochemical staining. Immunoblot analysis was performed as previously described [14] using anti-Bmi-1 antibody (1:50 dilution; Abcam) and anti-RKIP antibody (1:50 dilution; Abcam). A negative control was achieved by replacing the primary antibody with a normal IgG.…”

Section: Tissue Microarray and Immunohistochemistrymentioning

confidence: 99%

“…Staining intensity was scored as four grades: 0 for a complete absence of staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining. The extent of Bmi-1 staining was scored as follows: 0 for completely negative staining, 1 for tumors with less than 10 % of cells staining positive, and 2 for tumors with at least 10 % of cells staining positive [14]. The extent of RKIP staining was scored as four grades: 0 for completely negative staining, 1 for tumors with less than 10 % of cells staining positive, 2 for tumors with 10-50 % of cells staining positive, and 3 for tumors with more than 50 % of cells staining positive.…”

Section: Evaluation Of Immunostainingmentioning

confidence: 99%

“…Western blotting analysis was performed as previously described [14] using anti-Bmi-1 antibody (1:1,000 dilution; Cell Signaling Technology) and anti-RKIP antibody (1:2,000 dilution; Abcam).…”

Section: Western Blotting Analysismentioning

confidence: 99%

See 2 more Smart Citations

Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance

Chen

Lian

et al. 2015

Gastric Cancer

View full text Add to dashboard Cite

Background B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) and Raf kinase inhibitory protein (RKIP) are involved in cancer metastasis and chemotherapeutic resistance, respectively. In this study, we evaluated the association between Bmi-1 and RKIP and outcome of gastric cancer through clinical data analysis and in vitro experiments. Methods Bmi-1 expression and RKIP expression were observed in 107 cases of gastric cancer through use of tissue microarray technology to identify their correlations with clinicopathological parameters, patient survival, and susceptibility to chemotherapy. The correlation was confirmed in gastric cancer cell lines, analyzed further by gene overexpression and silencing analysis, a cell invasion assay, and a chemosensitivity test.Results Positive expression of Bmi-1 was highly correlated with T classification and clinical stage. Diminished or lost expression of RKIP was significantly associated with T classification, lymph node metastasis, distant metastasis, and clinical stage. Bmi-1 is negatively and RKIP is positively related to patient survival. Positive expression of Bmi-1 and negative expression of RKIP are associated with poor patient survival and modest efficacy of postoperative chemotherapy. A meaningfully inverse association between Bmi-1 and RKIP was found in tissue microarray studies, and was verified further in gastric cancer cell lines. Moreover, gene overexpression and silencing analysis indicated that RKIP might be regulated by Bmi-1. Furthermore, the impacts of Bmi-1 on cell invasion and chemotherapy resistance were rescued by knockdown of RKIP. Conclusions Our study implies that detection of Bmi-1 and RKIP is valuable in predicting patient survival and therapeutic response in gastric cancer, and the inverse association between Bmi-1 and RKIP reveals the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance.Y. Chen, G. Lian, and G. Ou are contributed equally to this work.Electronic supplementary material The online version of this article

show abstract

Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma

Huber

Albinger-Hegyi

Soltermann

et al. 2011

Cancer

View full text Add to dashboard Cite

Cytoplasmic Bmi-1 expression, an absence of p16 expression, and especially the combination of those 2 predictive markers were correlated negatively with disease-specific and recurrence-free survival in patients with oropharyngeal cancer. Therefore, the current results indicate that these may be applicable as predictive markers in combination with other factors to select patients for more aggressive treatment and follow-up.

show abstract

Bmi‐1 expression predicts prognosis for patients with gastric carcinoma

Abstract: Bmi-1 may serve as a valuable marker for diagnosis and prognosis of GC.

Cited by 73 publications

References 35 publications

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance

Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma

Contact Info

Product

Resources

About